Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
about
Hypomethylating agents for adult patients with acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaSafety and efficacy of azacitidine in myelodysplastic syndromesUse of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendationsEpigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineSafety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesTargeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsThe blind men and the AML elephant: can we feel the progress?Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeInfections in myelodysplastic syndromesMyelodysplastic syndromes: what do hospitalists need to know?Clinical Results of Hypomethylating Agents in AML TreatmentProgress in acute myeloid leukemiaRefractory anemia with ring sideroblasts and RARS with thrombocytosisOxidative stress induces monocyte necrosis with enrichment of cell-bound albumin and overexpression of endoplasmic reticulum and mitochondrial chaperonesManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome.Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupMyelodysplastic syndromes: the role of the immune system in pathogenesis.Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.Thrombocytopenia in patients with myelodysplastic syndromes.Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Demethylating Agents in the Treatment of CancerCombination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.Prolonged responses in patients with MDS and CMML treated with azacitidine and etanerceptLow-dose azacitidine after allogeneic stem cell transplantation for acute leukemiaEpigenetic therapies in MDS and AMLReport of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromesOutcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyTreatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).Current therapy of myelodysplastic syndromes
P2860
Q24186284-3628F5C0-9204-4126-B454-896916AEF82EQ24234645-7A06123C-A05D-45CF-9457-64AEF0F6066BQ24596561-0DF799CB-6D14-4256-B22F-7931FB839378Q24605618-04C65E7D-1A5B-41CD-899B-DBC399CACF28Q24608659-D62047FE-5185-4EE5-9BEA-91C735E6BE74Q24632949-9501B76B-CED8-475E-A32C-4F7A48F90700Q26744080-F172BF2B-0599-47D9-BB7D-4B466E5414FFQ26745731-1E0528DC-9C7D-4A12-9510-2414357C94AAQ26749614-581067D6-26BE-493C-AD96-B03283179155Q26770391-D92D1142-DBB8-47FA-860A-B888E41BEECFQ26829132-61A7872B-7745-419A-A1C3-083848BDDBA1Q26859275-331A6C3C-014E-414F-AAF4-B69B207D1DF6Q27011372-2D63CEBE-8FD6-4199-A38B-A6E367454BD6Q27022725-7A0143E5-14A5-4A23-86C4-99E634D61CEFQ27024006-04124750-7690-45B8-ABAE-2FA0DDB7C6F4Q28083238-1E90BADB-DEC2-41F1-92EA-DDF5900B3C1AQ28488971-B1F23A67-CB1A-4977-A190-3BB0F0448C29Q30235355-6695BB96-DB6D-428E-936B-7A2693E7FD77Q30837329-0898F5C7-8C04-4ABC-B9EE-6E56FB65B07EQ31163049-6D242286-1D44-4EBA-B1F4-EBB309AEE3E0Q33351527-4A7946B6-E4E5-4B8E-85CA-05F80517F7A0Q33382047-6EBAF3EF-6A40-4F14-84D1-B092C580F8E3Q33389465-9F193CCB-578D-4C59-911D-E214DD9CB054Q33390639-3ED7A1E5-89D2-4066-A048-DBFBB5F096A8Q33392293-ED87A3F1-7008-443F-832B-B19313D65BB0Q33393647-70A0425A-72E1-450E-99C9-6B752A40661EQ33415466-87F80B1D-44DF-46FC-BECF-C07452CBF5A8Q33417145-9804529F-2DBF-45B9-AC56-51252BA7B901Q33434768-709FF5A9-6533-4B7B-B3E0-68376B024258Q33586751-90AC6396-908F-4FFB-8A52-02353546A0BDQ33621141-5EF48C7D-9432-4CB3-9538-756EB2B642C0Q33678040-AD430444-8AEA-4B39-A955-628DF82AF5E1Q33798842-44B825D7-06AC-4C7D-B5F3-194486E8CC83Q33828803-4132C256-8347-45CD-8567-F09BDD1084B2Q33861150-326B68AE-6C7E-4878-99E6-167B6A7970C2Q33863567-3E4823D3-2652-4C37-9184-70458F7CB284Q33876297-95C89F67-005E-4972-8861-4E1954F74E2AQ33914183-A5B9CF64-789D-4633-80B8-2304E6C77F38Q33920750-CAB9CC25-4B9F-48E5-862F-34AD2AD7785FQ34013796-2B25FF53-8247-4A69-955F-5D7F329314FC
P2860
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@ast
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@en
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@nl
type
label
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@ast
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@en
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@nl
prefLabel
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@ast
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@en
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@nl
P2093
P356
P1476
Further analysis of trials wit ...... e Cancer and Leukemia Group B.
@en
P2093
Bercedis L Peterson
David R McKenzie
James F Holland
Jay T Backstrom
Lewis R Silverman
P304
P356
10.1200/JCO.2005.05.4346
P407
P577
2006-08-01T00:00:00Z